Adicet Bio, Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Adicet Bio, Inc. (ACET) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $1.44 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-05
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $1.44M, a 50.45% decline year-over-year.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $1.30M, a 59.03% decline year-over-year.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $2.53M, a 62.68% decline year-over-year.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $2.91M, a 51.57% decline year-over-year.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $14.27M, a 35.83% decline from fiscal 2024.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.23M, a 9.74% increase from fiscal 2023.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $20.26M, a 18.29% increase from fiscal 2022.
- Adicet Bio, Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $17.13M, a 36.89% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month as first filed | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1.44M 10-Q · filed 2026-08-05 | $2.74M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2026-03-31 | $1.30M 10-Q · filed 2026-08-05 | |||||
| 2025-12-31 | $14.27M 10-K · filed 2026-03-12 | |||||
| 2025-09-30 | $2.53M 10-Q · filed 2025-11-05 | $5.44M derived: sum of 2 quarters · filed 2026-08-05 | $8.62M derived: sum of 3 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $2.91M 10-Q · filed 2026-08-05 | $6.09M derived: sum of 2 quarters · filed 2026-08-05 | ||||
| 2025-03-31 | $3.18M 10-Q · filed 2026-08-05 | |||||
| 2024-12-31 | $22.23M 10-K · filed 2026-03-12 | |||||
| 2024-09-30 | $6.78M 10-Q · filed 2025-11-05 | $12.78M derived: sum of 2 quarters · filed 2025-11-05 | $18.46M derived: sum of 3 quarters · filed 2025-11-05 | |||
| 2024-06-30 | $6.00M 10-Q · filed 2025-11-05 | $11.68M derived: sum of 2 quarters · filed 2025-11-05 | ||||
| 2024-03-31 | $5.68M 10-Q · filed 2025-11-05 | |||||
| 2023-12-31 | $20.26M 10-K · filed 2025-03-06 | |||||
| 2023-09-30 | $5.56M 10-Q · filed 2024-11-06 | $10.58M derived: sum of 2 quarters · filed 2024-11-06 | $15.35M derived: sum of 3 quarters · filed 2024-11-06 | |||
| 2023-06-30 | $5.02M 10-Q · filed 2024-11-06 | $9.79M derived: sum of 2 quarters · filed 2024-11-06 | ||||
| 2023-03-31 | $4.76M 10-Q · filed 2024-11-06 | |||||
| 2022-12-31 | $17.13M 10-K · filed 2024-03-19 | |||||
| 2022-09-30 | $4.19M 10-Q · filed 2023-11-08 | $8.53M derived: sum of 2 quarters · filed 2023-11-08 | $12.88M derived: sum of 3 quarters · filed 2023-11-08 | |||
| 2022-06-30 | $4.33M 10-Q · filed 2023-11-08 | $8.69M derived: sum of 2 quarters · filed 2023-11-08 | ||||
| 2022-03-31 | $4.35M 10-Q · filed 2023-11-08 | |||||
| 2021-12-31 | $12.51M 10-K · filed 2023-03-15 | |||||
| 2021-09-30 | $2.53M 10-Q · filed 2022-11-08 | $5.19M derived: sum of 2 quarters · filed 2022-11-08 | $8.23M derived: sum of 3 quarters · filed 2022-11-08 | |||
| 2021-06-30 | $2.66M 10-Q · filed 2022-11-08 | $5.70M derived: sum of 2 quarters · filed 2022-11-08 | ||||
| 2021-03-31 | $3.04M 10-Q · filed 2022-11-08 | |||||
| 2020-12-31 | $5.26M 10-K · filed 2022-03-15 | |||||
| 2020-09-30 | $2.97M 10-Q · filed 2021-11-10 | $3.32M derived: sum of 2 quarters · filed 2021-11-10 | $3.62M derived: sum of 3 quarters · filed 2021-11-10 | |||
| 2020-06-30 | $351.00K 10-Q · filed 2021-11-10 | $759.00K 10-Q · filed 2020-07-30 | $650.00K derived: sum of 2 quarters · filed 2021-11-10 | |||
| 2020-03-31 | $299.00K 10-Q · filed 2021-11-10 | $975.00K 10-Q · filed 2020-05-07 | ||||
| 2019-12-31 | $1.18M 10-K · filed 2021-03-12 | $3.69M 10-K · filed 2020-03-12 | ||||
| 2019-09-30 | $391.00K 10-Q · filed 2020-11-05 | $1.20M 10-Q · filed 2019-11-05 | $614.00K derived: sum of 2 quarters · filed 2020-11-05 | $865.00K derived: sum of 3 quarters · filed 2020-11-05 | ||
| 2019-06-30 | $223.00K 10-Q · filed 2020-11-05 | $944.00K 10-Q · filed 2019-08-14 | $474.00K derived: sum of 2 quarters · filed 2020-11-05 | |||
| 2019-03-31 | $251.00K 10-Q · filed 2020-11-05 | $662.00K 10-Q · filed 2019-05-15 | ||||
| 2018-12-31 | $2.48M 10-K · filed 2021-03-12 | $1.93M 10-K · filed 2019-03-18 | ||||
| 2018-09-30 | $629.00K 10-Q · filed 2019-11-05 | $1.03M derived: sum of 2 quarters · filed 2019-11-05 | $1.35M derived: sum of 3 quarters · filed 2019-11-05 | |||
| 2018-06-30 | $402.00K 10-Q · filed 2019-11-05 | $718.00K derived: sum of 2 quarters · filed 2019-11-05 | ||||
| 2018-03-31 | $316.00K 10-Q · filed 2019-11-05 | |||||
| 2017-12-31 | $470.00K 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |